ClinicalTrials.Veeva

Menu

Intraductal Secretin Stimulation Test: What Is the Proper Collection Time? (IDST)

Indiana University logo

Indiana University

Status

Completed

Conditions

Cholangiopancreatography, Endoscopic Retrograde

Treatments

Procedure: Intraductal secretin test (IDST)

Study type

Interventional

Funder types

Other

Identifiers

NCT03263481
1203008365

Details and patient eligibility

About

The aim is to evaluate the peak secretory flow rates and bicarbonate concentrations as determined by a 30 minute intraductal secretin stimulation test in patients with a low likelihood of pancreatic pathology and to compare these data to those obtained from our historical patients with suspected chronic pancreatitis. These will be patients in which inadvertent pancreatic cannulation occurs during therapeutic endoscopic retrograde cholangiopancreatography (ERCP) for biliary indications . All study subjects will receive a 5 day follow-up phone call. Enrollment goal is 36 subjects.

Enrollment

8 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Male or female patients ≥ 18 years of age referred to Indiana University Health, University Hospital for ERCP for a biliary indication, at the discretion of the treating MD (e.g. suspected common bile duct stone, initial post-liver transplant evaluation, suspected or confirmed cholangiocarcinoma, suspected primary sclerosing cholangitis -- see exclusion criterion #12)

Exclusion criteria

  1. Pregnant woman or breast feeding
  2. Age <18 years
  3. Patient unable to give informed consent
  4. Patient with a history of pancreatic surgery
  5. Patient with a history of pancreatic cancer
  6. Patient with a history of acute or chronic pancreatitis
  7. Patient with radiographic evidence of acute or chronic pancreatitis on CT, MRCP, or EUS
  8. Patient with a current or prior history of average daily alcohol consumption of greater than 60 g per day for more than 2 years
  9. Patient with a history of cigarette smoking greater that 20 pack-years
  10. Patient with a history of pancreas divisum
  11. Evidence of chronic pancreatitis on pancreatogram during ERCP
  12. ERCP for an isolated biliary indication with previous biliary sphincterotomy or for biliary stent exchange, when pancreatic entry should easily be avoided by the endoscopist.
  13. History of allergy or adverse reactions to secretin

Trial design

Primary purpose

Basic Science

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

8 participants in 1 patient group

ERCP with inadvertent pancreatic cannulation
Experimental group
Description:
Subjects undergoing ERCP for a biliary indication in which inadvertent pancreatic cannulation occurs will undergo intraductal secretin testing per the study protocol.
Treatment:
Procedure: Intraductal secretin test (IDST)

Trial contacts and locations

1

Loading...

Central trial contact

Evan L Fogel, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems